Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis

M. Pulicken, C. N. Bash, K. Costello, A. Said, C. Cuffari, J. L. Wilterdink, J. M. Rogg, P. Mills, Peter A. Calabresi

Research output: Contribution to journalArticle

Abstract

We conducted an open-label pilot clinical trial to evaluate the safety and efficacy of adding oral azathioprine to the treatment regimen of 15 multiple sclerosis patients breaking through monotherapy with interferon β-1b. There were no serious adverse events. Gastrointestinal side effects and leukopenia were the most common adverse events and limited dose escalation. There was a 65% reduction in the number of gadolinium-enhanced magnetic resonance imaging (MRI) lesions on combination therapy compared to the baseline values (P =0.003). A total WBC count less than 4800/mm3 was the best predictor of MRI response.

Original languageEnglish (US)
Pages (from-to)169-174
Number of pages6
JournalMultiple Sclerosis
Volume11
Issue number2
DOIs
StatePublished - Apr 1 2005

Keywords

  • 6-thioguanine
  • Immunosuppression
  • MRI
  • Therapy
  • Toxicity

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this